Publications 2024

Heinrich MC, Jones RL, George S, Gelderblom H, Schöffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Reichmann W, Sprott K, Achour H et al. (2024)
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
Nat Med, 30 (2), 498-506
DOI 10.1038/s41591-023-02734-5, PubMed 38182785

Zhou Y, Ray PS, Zhu J, Stein F, Rettel M, Sekaran T, Sahadevan S, Perez-Perri JI, Roth EK, Myklebost O, Meza-Zepeda LA, von Deimling A, Fu C, Brosig AN, Boye K, Nathrath M, Blattmann C, Lehner B, Hentze MW, Kulozik AE (2024)
Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma
Nat Commun, 15 (1), 2810
DOI 10.1038/s41467-024-47031-y, PubMed 38561347

Publications 2023

Berndsen M, Renberg S, Hølmebakk T, Hancke E, Puls F, Karlsson F, Stoldt S, Bjerkehagen B, Haglund de Flon F, Muth A, Papakonstantinou A, Boye K, Lindskog S (2023)
Long-term outcome after surgical resection of non-high-risk gastrointestinal stromal tumours without adjuvant therapy
Br J Surg, 110 (12), 1857-1862
DOI 10.1093/bjs/znad309, PubMed 37758514

Boye K, Gorunova L, Gunawan B, Hompland I, Sander B, Panagopoulos I, Langer C, Golas M, Heim S, Füzesi L, Hølmebakk T, Micci F (2023)
Genomic Complexity as a Biomarker to De-Escalate Adjuvant Imatinib Treatment in High-Risk Gastrointestinal Stromal Tumor
JCO Precis Oncol, 7, e2200351
DOI 10.1200/PO.22.00351, PubMed 36724411

Gelderblom H, Jones RL, Blay JY, George S, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Harrow B, Becker C, Reichmann W, Sherman ML et al. (2023)
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study
Eur J Cancer, 192, 113245
DOI 10.1016/j.ejca.2023.113245, PubMed 37598656

Høland M, Berg KCG, Eilertsen IA, Bjerkehagen B, Kolberg M, Boye K, Lingjærde OC, Guren TK, Mandahl N, van den Berg E, Palmerini E, Smeland S, Picci P, Mertens F, Sveen A, Lothe RA (2023)
Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets
EBioMedicine, 97, 104829
DOI 10.1016/j.ebiom.2023.104829, PubMed 37837931

Janik AM, Terlecka A, Spałek MJ, Boye K, Szostakowski B, Chmiel P, Szumera-Ciećkiewicz A, Bobak K, Świtaj T, Rutkowski P, Czarnecka AM (2023)
Diagnostics and Treatment of Extrameningeal Solitary Fibrous Tumors
Cancers (Basel), 15 (24)
DOI 10.3390/cancers15245854, PubMed 38136399

Namløs HM, Khelik K, Nakken S, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2023)
Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential
Mol Oncol, 17 (11), 2432-2450
DOI 10.1002/1878-0261.13514, PubMed 37622176

van Ewijk R, Cleirec M, Herold N, le Deley MC, van Eijkelenburg N, Boudou-Rouquette P, Risbourg S, Strauss SJ, Palmerini E, Boye K, Kager L, Hecker-Nolting S, Marchais A, Gaspar N, FOSTER Consortium (Fight OsteoSarcoma Through European Research), work package 3 on recurrent/refractory osteosarcoma trials (2023)
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?
Cancer Treat Rev, 120, 102625
DOI 10.1016/j.ctrv.2023.102625, PubMed 37738712

Wallander K, Öfverholm I, Boye K, Tsagkozis P, Papakonstantinou A, Lin Y, Haglund de Flon F (2023)
Sarcoma care in the era of precision medicine
J Intern Med, 294 (6), 690-707
DOI 10.1111/joim.13717, PubMed 37643281

Publications 2022

Boye K, Lobmaier I, Kobbeltvedt MR, Thorkildsen J, Taksdal I, Bjerkehagen B, Bruland ØS, Zaikova O, Sundby Hall K, Hompland I (2022)
Real-world evidence on perioperative chemotherapy in localized soft tissue sarcoma of the extremities and trunk wall; a population-based study
Acta Oncol, 61 (7), 793-800
DOI 10.1080/0284186X.2022.2082259, PubMed 35698755

Georgiesh T, Aggerholm-Pedersen N, Schöffski P, Zhang Y, Napolitano A, Bovée JVMG, Hjelle Å, Tang G, Spalek M, Nannini M, Swanson D, Baad-Hansen T, Sciot R, Hesla AC, Huang P, Dorleijn D, Haugland HK, Lacambra M, Skoczylas J, Pantaleo MA, Haas RL, Meza-Zepeda LA, Haller F, Czarnecka AM, Loong H et al. (2022)
Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour
Br J Cancer, 127 (10), 1793-1798
DOI 10.1038/s41416-022-01959-4, PubMed 36030294

Gorunova L, Boye K, Panagopoulos I, Berner JM, Bjerkehagen B, Hompland I, Lobmaier I, Hølmebakk T, Hveem TS, Heim S, Micci F (2022)
Cytogenetic and molecular analyses of 291 gastrointestinal stromal tumors: site-specific cytogenetic evolution as evidence of pathogenetic heterogeneity
Oncotarget, 13, 508-517
DOI 10.18632/oncotarget.28209, PubMed 35284037

Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen WT, Dei Tos PA, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hardes J, Hartmann W, Healey J, Italiano A, Jones RL et al. (2022)
Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts
Cancer Treat Rev, 112, 102491
DOI 10.1016/j.ctrv.2022.102491, PubMed 36502615

Publications 2021

Boye K, Longhi A, Guren T, Lorenz S, Næss S, Pierini M, Taksdal I, Lobmaier I, Cesari M, Paioli A, Løndalen AM, Setola E, Hompland I, Meza-Zepeda LA, Sundby Hall K, Palmerini E (2021)
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Cancer Immunol Immunother, 70 (9), 2617-2624
DOI 10.1007/s00262-021-02876-w, PubMed 33580363

Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dufresne A, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F et al. (2021)
Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol, 33 (1), 20-33
DOI 10.1016/j.annonc.2021.09.005, PubMed 34560242

Georgiesh T, Namløs HM, Sharma N, Lorenz S, Myklebost O, Bjerkehagen B, Meza-Zepeda LA, Boye K (2021)
Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumour
Pathology, 53 (6), 713-719
DOI 10.1016/j.pathol.2020.11.010, PubMed 33745702

Hølmebakk T, Boye K (2021)
ASO Author Reflections: How to Identify Patients at Genuinely High Risk of Recurrence from Localized Gastrointestinal Stromal Tumor of the Stomach?
Ann Surg Oncol, 28 (11), 6846-6847
DOI 10.1245/s10434-021-09608-5, PubMed 33687615

Hølmebakk T, Boye K (2021)
Correction to: ASO Author Reflections: How to Identify Patients at Genuinely High Risk of Recurrence from Localized Gastrointestinal Stromal Tumor of the Stomach?
Ann Surg Oncol, 28 (Suppl 3), 873
DOI 10.1245/s10434-021-09939-3, PubMed 33829360

Hølmebakk T, Wiedswang AM, Meza-Zepeda LA, Hompland I, Lobmaier IVK, Berner JM, Stoldt S, Boye K (2021)
Integrating Anatomical, Molecular and Clinical Risk Factors in Gastrointestinal Stromal Tumor of the Stomach
Ann Surg Oncol, 28 (11), 6837-6845
DOI 10.1245/s10434-021-09605-8, PubMed 33651216

Mariathasan AB, Boye K, Dueland S, Flatmark K, Larsen SG (2021)
Metastases in locally advanced rectal cancer undergoing curatively intended treatment
Eur J Surg Oncol, 47 (9), 2377-2383
DOI 10.1016/j.ejso.2021.04.023, PubMed 34049768

Peneder P, Stütz AM, Surdez D, Krumbholz M, Semper S, Chicard M, Sheffield NC, Pierron G, Lapouble E, Tötzl M, Ergüner B, Barreca D, Rendeiro AF, Agaimy A, Boztug H, Engstler G, Dworzak M, Bernkopf M, Taschner-Mandl S, Ambros IM, Myklebost O, Marec-Bérard P, Burchill SA, Brennan B, Strauss SJ et al. (2021)
Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden
Nat Commun, 12 (1), 3230
DOI 10.1038/s41467-021-23445-w, PubMed 34050156

Publications 2020

Dagenborg VJ, Marshall SE, Yaqub S, Grzyb K, Boye K, Lund-Iversen M, Høye E, Berstad AE, Fretland ÅA, Edwin B, Ree AH, Flatmark K (2020)
Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases
Cancer Biol Ther, 21 (5), 432-440
DOI 10.1080/15384047.2020.1721252, PubMed 32098573

Fleten KG, Lund-Andersen C, Waagene S, Abrahamsen TW, Mørch Y, Boye K, Torgunrud A, Flatmark K (2020)
Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models
Transl Oncol, 13 (8), 100793
DOI 10.1016/j.tranon.2020.100793, PubMed 32447231

Georgiesh T, Boye K, Bjerkehagen B (2020)
A novel risk score to predict early and late recurrence in solitary fibrous tumour
Histopathology, 77 (1), 123-132
DOI 10.1111/his.14078, PubMed 31991494

Lachota M, Vincenti M, Winiarska M, Boye K, Zagożdżon R, Malmberg KJ (2020)
Prospects for NK Cell Therapy of Sarcoma
Cancers (Basel), 12 (12)
DOI 10.3390/cancers12123719, PubMed 33322371

Palmerini E, Leithner A, Windhager R, Gosheger G, Boye K, Laitinen M, Hardes J, Traub F, Jutte P, Willegger M, Casanova J, Setola E, Righi A, Picci P, Donati DM, Ferrari S (2020)
Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS)
Sci Rep, 10 (1), 10853
DOI 10.1038/s41598-020-66579-5, PubMed 32616718

Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K (2020)
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873

Publications 2019

Namløs HM, Boye K, Meza-Zepeda LA (2019)
Cell-free DNA in blood as a noninvasive insight into the sarcoma genome
Mol Aspects Med, 72, 100827
DOI 10.1016/j.mam.2019.10.004, PubMed 31703948

Publications 2018

Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahmi M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desar IME, Benjamin RS, Blay JY, Broto JM, Casali PG, Gelderblom H, Grignani G, Gronchi A, Hall KS, Mir O, Rutkowski P et al. (2018)
Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series
JAMA Oncol, 4 (9), e180219
DOI 10.1001/jamaoncol.2018.0219, PubMed 29800950

Hompland I, Hølmebakk T, Boye K, Stoldt S, Bjerkehagen B, Berner JM, Wiedswang AM, Revheim ME, Poulsen JP, Hall KS, Bruland ØS (2018)
[Not Available]
Tidsskr Nor Laegeforen, 138 (15)
DOI 10.4045/tidsskr.18.0200, PubMed 30277049

Hølmebakk T, Hompland I, Bjerkehagen B, Stoldt S, Bruland ØS, Hall KS, Boye K (2018)
Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study
Ann Surg Oncol, 25 (5), 1133-1139
DOI 10.1245/s10434-018-6353-5, PubMed 29435684

Johnsen B, Fasmer KE, Boye K, Rosendahl K, Trovik C, Biermann M, Aukland SM (2018)
Added value of F-18-FDG PET-CT in staging of Ewing sarcoma in children and young adults
Eur. J. Hybrid Imag., 2 (1), 13
DOI 10.1186/s41824-018-0031-5

Longhi A, Paioli A, Palmerini E, Cesari M, Abate ME, Setola E, Spinnato P, Donati D, Hompland I, Boye K (2018)
Pazopanib in relapsed osteosarcoma patients: report on 15 cases
Acta Oncol, 58 (1), 124-128
DOI 10.1080/0284186X.2018.1503714, PubMed 30207179

Namløs HM, Boye K, Mishkin SJ, Barøy T, Lorenz S, Bjerkehagen B, Stratford EW, Munthe E, Kudlow BA, Myklebost O, Meza-Zepeda LA (2018)
Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor
Mol Cancer Ther, 17 (11), 2473-2480
DOI 10.1158/1535-7163.MCT-18-0174, PubMed 30097488

Strauss SJ, Anninga J, Baglio R, Baumhoer D, Behjati S, Bielack S, Boye K, Broto JM, Cleton-Jansen AM, Degasperi A, Evans A, Fagioli F, Fiocco M, Gaspar N, Heymann D, Hindi N, Lancia C, Myklebost O, Nathrath M, Redini F, Scotlandi K, Tirtei E, Vanden Eynden M, Whelan J (2018)
Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma
Clin. Sarcoma Res., 8, 17
DOI 10.1186/s13569-018-0103-0

Publications 2017

Boye K, Jebsen NL, Zaikova O, Knobel H, Løndalen AM, Trovik CS, Monge OR, Hall KS (2017)
Denosumab in patients with giant-cell tumor of bone in Norway: results from a nationwide cohort
Acta Oncol, 56 (3), 479-483
DOI 10.1080/0284186X.2016.1278305, PubMed 28105885

Egeland EV, Boye K, Park D, Synnestvedt M, Sauer T, Oslo Breast Cancer Consortium (OSBREAC), Naume B, Borgen E, Mælandsmo GM (2017)
Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer
Breast Cancer Res Treat, 162 (1), 127-137
DOI 10.1007/s10549-016-4096-1, PubMed 28058579

Hompland I, Bruland ØS, Hølmebakk T, Poulsen JP, Stoldt S, Hall KS, Boye K (2017)
Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort
Acta Oncol, 56 (10), 1317-1323
DOI 10.1080/0284186X.2017.1330555, PubMed 28557540

Namløs HM, Zaikova O, Bjerkehagen B, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2017)
Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report
BMC Cancer, 17 (1), 29
DOI 10.1186/s12885-016-2992-8, PubMed 28061772

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742

Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, Casali PG, Provenzano S, Kawai A (2017)
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma
Oncologist, 23 (1), 62-70
DOI 10.1634/theoncologist.2017-0161, PubMed 28754721

Publications 2016

Boye K, Jacob H, Frikstad KA, Nesland JM, Maelandsmo GM, Dahl O, Nesbakken A, Flatmark K (2016)
Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy
Cancer Med, 5 (8), 1840-9
DOI 10.1002/cam4.766, PubMed 27273130

Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K (2016)
Expression and clinical significance of Wee1 in colorectal cancer
Tumour Biol, 37 (9), 12133-12140
DOI 10.1007/s13277-016-5081-3, PubMed 27220319

Hompland I, Bruland ØS, Ubhayasekhera K, Bergquist J, Boye K (2016)
Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour
Clin Sarcoma Res, 6, 21
DOI 10.1186/s13569-016-0062-2, PubMed 27999655

Johnsen B, Fasmer KE, Boye K, Rosendahl K, Trovik C, Biermann M, Aukland SM (2016)
Estimated cumulative radiation dose received by diagnostic imaging during staging and treatment of operable Ewing sarcoma 2005-2012
Pediatr Radiol, 47 (1), 82-88
DOI 10.1007/s00247-016-3720-x, PubMed 27815616

Rud AK, Boye K, Fodstad Ø, Juell S, Jørgensen LH, Solberg S, Helland Å, Brustugun OT, Mælandsmo GM (2016)
Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
Diagn Pathol, 11 (1), 50
DOI 10.1186/s13000-016-0504-4, PubMed 27316334

Publications 2015

Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM (2015)
Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes
Clin Exp Metastasis, 32 (8), 755-67
DOI 10.1007/s10585-015-9742-1, PubMed 26349943

Johnsen B, Boye K, Rosendahl K, Biermann M, Trovik C, Aukland SM (2015)
F-18-FDG PET-CT in children and young adults with Ewing sarcoma diagnosed in Norway during 2005-2012: a national population-based study
Clin Physiol Funct Imaging, 36 (6), 441-446
DOI 10.1111/cpf.12247, PubMed 26039107

Prasmickaite L, Berge G, Bettum IJ, Aamdal S, Hansson J, Bastholt L, Øijordsbakken M, Boye K, Mælandsmo GM (2015)
Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial
Cancer Immunol Immunother, 64 (6), 769-76
DOI 10.1007/s00262-015-1686-4, PubMed 25832001

Publications 2014

Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K (2014)
High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting
Eur J Cancer, 51 (1), 9-17
DOI 10.1016/j.ejca.2014.10.020, PubMed 25466510

Ingebrigtsen VA, Boye K, Nesland JM, Nesbakken A, Flatmark K, Fodstad Ø (2014)
B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome
BMC Cancer, 14, 602
DOI 10.1186/1471-2407-14-602, PubMed 25139714

Panagopoulos I, Bjerkehagen B, Gorunova L, Berner JM, Boye K, Heim S (2014)
Several fusion genes identified by whole transcriptome sequencing in a spindle cell sarcoma with rearrangements of chromosome arm 12q and MDM2 amplification
Int J Oncol, 45 (5), 1829-36
DOI 10.3892/ijo.2014.2605, PubMed 25176350

Panagopoulos I, Gorunova L, Bjerkehagen B, Boye K, Heim S (2014)
Chromosome aberrations and HEY1-NCOA2 fusion gene in a mesenchymal chondrosarcoma
Oncol Rep, 32 (1), 40-4
DOI 10.3892/or.2014.3180, PubMed 24839999

Publications 2013

Boye K, Del Prever AB, Eriksson M, Saeter G, Tienghi A, Lindholm P, Fagioli F, Skjeldal S, Ferrari S, Hall KS (2013)
High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study
Pediatr Blood Cancer, 61 (5), 840-5
DOI 10.1002/pbc.24868, PubMed 24254749

Friedman R, Boye K, Flatmark K (2013)
Molecular modelling and simulations in cancer research
Biochim Biophys Acta, 1836 (1), 1-14
DOI 10.1016/j.bbcan.2013.02.001, PubMed 23416097

Rud AK, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K (2013)
Clinical significance of disseminated tumour cells in non-small cell lung cancer
Br J Cancer, 109 (5), 1264-70
DOI 10.1038/bjc.2013.450, PubMed 23942067

Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM (2013)
Osteopontin is a prognostic biomarker in non-small cell lung cancer
BMC Cancer, 13, 540
DOI 10.1186/1471-2407-13-540, PubMed 24215488

Publications 2012

Boye K, Nesland JM, Sandstad B, Haugland Haugen M, Mælandsmo GM, Flatmark K (2012)
EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
Br J Cancer, 107 (4), 667-74
DOI 10.1038/bjc.2012.293, PubMed 22782346

Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O (2012)
B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer
Int J Cancer, 131 (11), 2528-36
DOI 10.1002/ijc.27566, PubMed 22473715

Rud AK, Lund-Iversen M, Berge G, Brustugun OT, Solberg SK, Mælandsmo GM, Boye K (2012)
Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer
BMC Cancer, 12, 333
DOI 10.1186/1471-2407-12-333, PubMed 22853000

Schee K, Boye K, Abrahamsen TW, Fodstad Ø, Flatmark K (2012)
Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer
BMC Cancer, 12, 505
DOI 10.1186/1471-2407-12-505, PubMed 23121918

Schee K, Flatmark K, Holm R, Boye K, Paus E (2012)
Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients (vol 33, pg 73, 2012)
Tumor Biol., 33 (4), 1263-1264
DOI 10.1007/s13277-012-0407-2

Publications 2011

Berge G, Pettersen S, Grotterød I, Bettum IJ, Boye K, Mælandsmo GM (2011)
Osteopontin--an important downstream effector of S100A4-mediated invasion and metastasis
Int J Cancer, 129 (4), 780-90
DOI 10.1002/ijc.25735, PubMed 20957651

Flatmark K, Borgen E, Nesland JM, Rasmussen H, Johannessen HO, Bukholm I, Rosales R, Hårklau L, Jacobsen HJ, Sandstad B, Boye K, Fodstad Ø (2011)
Disseminated tumour cells as a prognostic biomarker in colorectal cancer
Br J Cancer, 104 (9), 1434-9
DOI 10.1038/bjc.2011.97, PubMed 21448171

Schee K, Flatmark K, Holm R, Boye K, Paus E (2011)
Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients
Tumour Biol, 33 (1), 73-83
DOI 10.1007/s13277-011-0247-5, PubMed 22006279

Publications 2010

Boye K, Nesland JM, Sandstad B, Mælandsmo GM, Flatmark K (2010)
Nuclear S100A4 is a novel prognostic marker in colorectal cancer
Eur J Cancer, 46 (16), 2919-25
DOI 10.1016/j.ejca.2010.07.013, PubMed 20719498

Grotterød I, Maelandsmo GM, Boye K (2010)
Signal transduction mechanisms involved in S100A4-induced activation of the transcription factor NF-kappaB
BMC Cancer, 10, 241
DOI 10.1186/1471-2407-10-241, PubMed 20507646

Publications 2009

Boye K, Maelandsmo GM (2009)
S100A4 and metastasis: a small actor playing many roles
Am J Pathol, 176 (2), 528-35
DOI 10.2353/ajpath.2010.090526, PubMed 20019188

Publications 2008

Boye K, Grotterød I, Aasheim HC, Hovig E, Maelandsmo GM (2008)
Activation of NF-kappaB by extracellular S100A4: analysis of signal transduction mechanisms and identification of target genes
Int J Cancer, 123 (6), 1301-10
DOI 10.1002/ijc.23617, PubMed 18548584

Publications 2007

Boye K (2007)
The metastasis-promoting protein S100A4: expression, regulation and biological function
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 500, 1 b. (flere pag.)
BIBSYS 070877556, ISBN 978-82-8072-427-4

Publications 2006

Boye K, Andersen K, Tveito S, Øyjord T, Maelandsmo GM (2006)
Interferon-gamma-induced suppression of S100A4 transcription is mediated by the class II transactivator
Tumour Biol, 28 (1), 27-35
DOI 10.1159/000097700, PubMed 17143014

Publications 2003

Andersen K, Smith-Sørensen B, Pedersen KB, Hovig E, Myklebost O, Fodstad Ø, Maelandsmo GM (2003)
Interferon-gamma suppresses S100A4 transcription independently of apoptosis or cell cycle arrest
Br J Cancer, 88 (12), 1995-2001
DOI 10.1038/sj.bjc.6600998, PubMed 12799648

Publications 2002

Pedersen KB, Nesland JM, Fodstad Ø, Maelandsmo GM (2002)
Expression of S100A4, E-cadherin, alpha- and beta-catenin in breast cancer biopsies
Br J Cancer, 87 (11), 1281-6
DOI 10.1038/sj.bjc.6600624, PubMed 12439718

Publications 1998

Ree AH, Bjørnland K, Brünner N, Johansen HT, Pedersen KB, Aasen AO, Fodstad O (1998)
Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells
Clin Exp Metastasis, 16 (3), 205-15
DOI 10.1023/a:1006584624061, PubMed 9568638